(917) 310-3371
PSA screening is a shared decision. An elevated value can have non-cancer causes and needs interpretation with prior values and clinical history. Under USPSTF, ages 55–69 require an individual discussion and routine screening at 70 or older is not recommended. Family history and other guidelines can affect the discussion.
Cancer screening looks for disease in people who do not have symptoms. Different tests target different cancers and apply to different risk groups. A screening visit reviews your age, history, prior tests and preferences to choose an appropriate plan. Symptoms or an abnormal screening result need diagnostic assessment rather than another routine screen.
A stool DNA test such as Cologuard, a PSA blood test, low-dose CT lung screening and a multi-cancer blood test do different jobs. A positive result is not by itself a cancer diagnosis. A negative result cannot rule out all cancer. Screening can also produce false positives, unnecessary procedures and overdiagnosis, so benefits and harms should be discussed.
USPSTF recommends colorectal screening for average-risk adults ages 45–75 and individual decisions at 76–85. Its lung recommendation covers ages 50–80 with at least 20 pack-years who currently smoke or quit within 15 years. PSA screening at ages 55–69 is an individual decision under USPSTF; routine screening at 70 or older is not recommended by that guideline. Other organizations may differ, and individual risks matter.
Review previous screening, family history, smoking exposure and symptoms. The clinician explains the recommended test, alternatives, possible results and follow-up. Cologuard is intended for selected average-risk screening; a positive stool screening result requires colonoscopy. High-risk history or concerning symptoms may require a different route from a mail-in stool test.
Bring prior reports and a family cancer history. Ask for the exact collection or imaging instructions. Some stool tests need a supplied kit, while colonoscopy has separate preparation. Tell the team about blood in stool, unexplained weight loss, a persistent new symptom or a previous abnormal result rather than presenting only a request for screening.
Galleri and other multi-cancer detection tests remain distinct from established guideline screening. The current manufacturer and NCI materials reviewed do not establish FDA approval of Galleri; an advisory panel vote is not approval. Such testing does not replace recommended breast, cervical, colorectal or eligible lung screening. Severe bleeding, marked breathing difficulty or other acute symptoms need urgent care.
Before testing, agree on who will review the result and arrange diagnostic follow-up. A positive multi-cancer signal can lead to additional testing without finding cancer. A negative result does not end recommended screening or assessment of symptoms. Track referrals until the receiving practice confirms the next step.
Confirm which tests Nao actually orders or collects, where imaging or colonoscopy occurs and who manages abnormal results. Ask about the test, visit and diagnostic follow-up costs separately.
PSA is a blood test used in a prostate cancer screening discussion; it does not diagnose cancer by itself. USPSTF recommends an individual decision for men age 55–69 after discussing benefits and harms, and recommends against routine screening at age 70 or older. Risk and previous results can change the clinical discussion. Bring records and decide with the clinician rather than assuming every adult needs PSA.
No. A high PSA is not by itself a prostate cancer diagnosis. Benign enlargement, inflammation and other factors can affect the result. The clinician reviews the level, prior results, symptoms and risk and may recommend repeat testing or urology assessment. Do not infer cancer or ignore the result from a portal flag alone.
Yes. A family history of prostate cancer and other risk factors can affect a screening discussion. Bring details about which relatives were affected and their ages at diagnosis. The clinician should weigh possible benefit against false positives, biopsy harms and overdiagnosis rather than ordering PSA automatically.
Check your exact plan's rules for the screening consultation and PSA laboratory test separately. A guideline recommendation does not establish network status or a zero copay for a particular visit. Ask whether the planned test is screening or a diagnostic follow-up and what costs apply.
Bring the actual PSA report and earlier values with their dates. A trend and the clinical context matter more than a single portal flag. Tell the clinician about urinary symptoms, prior prostate assessment and family history so the next test or referral can be selected rather than duplicated.
Start with the main cancer-screening page for colorectal, Galleri, cervical, PSA, and lung-screening planning across the Nao network.
Use the Cologuard page for direct at-home colorectal-screening booking and follow-up planning.
Compare stool-based screening and colonoscopy options with clear next-step guidance.
Review multi-cancer early-detection planning, who may consider Galleri, and what it does not replace.
Use the cervical-screening page for Pap smear questions, HPV co-testing context, and local women's-health clinic access.
Check low-dose CT eligibility, smoking-history thresholds, and how screening conversations can start locally.